Therapy News and Research

RSS

New book outlines cutting-edge approach to systematically address AD

ADEC Inc. - Worried about your memory? Many patients with Alzheimer's disease (AD) and individuals concerned about developing memory loss feel they have limited options. While there is no 'magic pill' to cure or prevent AD, a new book outlines a cutting-edge approach to systematically address this disease.

12 Jul 2012

BioControl Medical receives FDA approval to initiate second phase of CardioFit study for heart failure

BioControl Medical has announced U.S. Food and Drug Administration approval to begin the second phase of INOVATE-HF (INcrease Of VAgal TonE in Heart Failure), a global, multi-center, investigational device exemption (IDE) clinical study of the company's CardioFit system for heart failure.

12 Jul 2012

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

NOXXON Pharma today announced the treatment of the first cohort of three chronic lymphocytic leukemia (CLL) patients in a Phase IIa clinical trial of its NOX-A12 anti-CXCL12/SDF-1 (CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer.

12 Jul 2012

Man Therapy launches in Colorado

Man Therapy, a groundbreaking new approach to suicide prevention and other men's mental health issues, was launched in Colorado today. Man Therapy reshapes the conversation, using humor to cut through stigma and tackle issues like depression, divorce and even suicidal thoughts head on, the way a man would do it.

12 Jul 2012

Enrollment complete in Phase III IND study of Spinal Restoration's Biostat System

Spinal Restoration, Inc. announced today the completion of enrollment in the Phase III Investigational New Drug (IND) study of the Biostat System. The Phase III clinical trial is a 260-subject, randomized, blinded, placebo controlled study designed to assess the ability of the Biostat System to reduce pain and improve function in patients with chronic discogenic low back pain.

12 Jul 2012

Pain rehab may boost children’s ownership of self management

Pediatric pain rehabilitation may lead to an increased willingness to self-manage pain, which is associated with improvements in function and psychologic wellbeing, say researchers.

11 Jul 2012

Oligodendroglia cells: An interview with Jeffrey Rothstein

There are three principle cells in the brain: neurons and two types of glial cells. One type is called an astrocyte. These were well known to inactivate neurotransmitters like glutamate, and provide metabolic support to neurons.

11 Jul 2012

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has established the University of California San Francisco (UCSF) as the second enrolling site for its Phase II Merkel cell carcinoma clinical trial (OMS-I110).

11 Jul 2012

WHO working on consolidated HIV treatment guidelines

The WHO "says comprehensive HIV treatment strategies are needed in developing countries to overcome stigma and discrimination," because "often those in need of HIV treatment and prevention are unable to receive the services because of their social status," VOA News reports.

11 Jul 2012

Giving up smoking associated with weight gain

Giving up smoking is associated with an average weight gain of 4-5 kg after 12 months, most of which occurs within the first three months of quitting, finds a study published on bmj.com today.

11 Jul 2012

HIV infection risk reduced by same drugs that treat HIV

People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.

11 Jul 2012

Study investigates effect of SwabCap in catheter maintenance bundle

A disinfection cap used in IV therapy was the subject of an award-winning, multi-site study at a four-hospital, Chicago-area hospital system.

11 Jul 2012

Cylene's Pol I inhibitor activates p53 and selectively destroys cancer cells

Cylene Pharmaceuticals today announced that research collaborators at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia have established, for the first time, that RNA Polymerase I (Pol I) activity is essential for cancer cell survival and that its inhibition selectively activates p53 to kill tumors. Published today in Cancer Cell, the findings show that Cylene's Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant but not in normal cells.

11 Jul 2012

HIV and AIDS treatment: An interview with Charles Flexner, MD

The best estimates at the moment reckon that there are about 25 million people infected with HIV. Most of those are in resource-limited settings, including sub-Saharan Africa, South East Asia and India.

11 Jul 2012

DRCRF names 21 new Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 21 new Damon Runyon Fellows at its spring Fellowship Award Committee review.

11 Jul 2012

New method uses acoustic angiography to identify cancer in minutes

From the air, the twists and turns of rivers can easily be seen. In the body, however, tracing the twists and turns of blood vessels is difficult, but important. Vessel "bendiness" can indicate the presence and progression of cancer.

11 Jul 2012

New approach integrates rational drug design with supramolecular nanochemistry in cancer treatment

Researchers at Brigham and Women's Hospital (BWH) are the first to report a new approach that integrates rational drug design with supramolecular nanochemistry in cancer treatment.

11 Jul 2012

SRI International receives DoD grant to develop novel therapy for MS

The Department of Defense (DoD) has awarded SRI International a one-year grant to develop a novel therapy for multiple sclerosis (MS), an autoimmune nervous system disease that affects about 400,000 people in the United States and more than two million people worldwide. There is currently no cure for this disorder, which can impair vision and movement.

11 Jul 2012

Obese achieve functional improvements after trauma rehab

Obese patients participating in a rehabilitation program for orthopedic trauma can achieve meaningful functional independence before discharge, US research shows.

10 Jul 2012

Biomarkers predict benefit of targeted therapy in metastatic renal-cell cancer

In metastatic renal-cell cancer, the level of cytokines and angiogenic factors identify those patients with an aggressive disease course who derive the greatest benefit from treatment with the molecular-targeted therapy pazopanib, a retrospective analysis of clinical trials shows.

10 Jul 2012